Search Results
Jun 08, 2026, 04:00 ET Coachella Takes the Crown: U.S. Festivals Dominate the Inaugural 'Global Festival Attractiveness Index' ('Yanolja Festival Index')
builds on two foundational pillars: "Festival Attractiveness," which measures how positively an event is viewed and emotionally embraced by attendees, and "Festival Reputation," which captures how widely known and frequently discussed the event is across global social platforms.Using these two pillars
More news about: Yanolja Research
Jun 08, 2026, 03:56 ET Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT® in Aggressive Brain Cancer (Glioblastoma)
radiation exposure to healthy organs.About Curasight's uPAR theranostic platform Curasight's uPAR theranostic platform combines two key technologies - uTRACE® and uTREAT® - both targeting uPAR. uTRACE® is designed to deliver sensitive imaging for diagnosis, while uTREAT® offers a
More news about: Curasight
Jun 08, 2026, 03:53 ET Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT® in Aggressive Brain Cancer (Glioblastoma)
radiation exposure to healthy organs.About Curasight's uPAR theranostic platform Curasight's uPAR theranostic platform combines two key technologies - uTRACE® and uTREAT® - both targeting uPAR. uTRACE® is designed to deliver sensitive imaging for diagnosis, while uTREAT® offers a
More news about: Curasight
Jun 08, 2026, 03:29 ET LG Teams with NVIDIA to Shape the Future with M.A.P. (Mobility / AI Infra / Physical AI)
opportunities across the intelligent systems that will shape daily life and industry."1. Cooperation in Physical AI and RoboticsThe two companies will pursue a win-win strategy in the field of Physical AI, spanning manufacturing to robotics, by maximizing synergies based on each company's
More news about: LG
Jun 08, 2026, 03:04 ET DL Holdings' Fourth "Victoria Harbour Night Talk": The AI Wave: Global Investment & Hong Kong Opportunities
tone for the entire forum.1. Forum Insights: The AI Shock and the Reconstruction of Digital FinanceThe forum centered on two core themes: the impact of AI on traditional finance, and the reconstruction of digital financial models. It provided a comprehensive analysis of the
More news about: DL Holdings
Jun 08, 2026, 03:00 ET UGREEN Launches NASync DXP GT with a Focus on Speed, Performance, and Reliability
The new lineup includes two models, the DXP4800 GT and DXP2800 GT, which are designed to meet different storage needs while sharing the same core promise of performance, speed,
More news about: UGREEN Limited
Jun 08, 2026, 03:00 ET Real Estate Firm New York Residence, Inc. Visits Netherlands, Belgium, & Croatia
crowns two decades of growth, innovation, and client devotion. "We take immense pride in this 20-year journey and the milestones we've conquered," said Chief Financial Officer Richard Pino. Richard further added, "This achievement honors our employees' grit and our customers' loyalty."For two decades,
More news about: New York Residence, Inc.
Jun 08, 2026, 03:00 ET Real Estate Firm New York Residence, Inc. Visits Netherlands, Belgium, & Croatia
crowns two decades of growth, innovation, and client devotion. "We take immense pride in this 20-year journey and the milestones we've conquered," said Chief Financial Officer Richard Pino. Richard further added, "This achievement honors our employees' grit and our customers' loyalty."For two decades,
More news about: New York Residence, Inc.
Jun 08, 2026, 02:47 ET Aker BP increases ownership interest in Johan Sverdrup following redetermination
in Aker BP's accounts from the third quarter of 2026.Aker BP will receive an additional 2.2 million barrels of oil equivalent over the next two years, reflecting the reallocation of historic production volumes. Aker BP will pay approximately NOK 300 million before tax, reflecting the
More news about: Aker BP ASA
Jun 08, 2026, 00:41 ET A New Lease of Life: Stories of Hope, Survivorship and Second Chances with Apollo Hospitals
the risks posed by his condition. Step by step, treatment progressed. What followed was a journey of courage, perseverance and trust. Today, more than two and a half years later, he remains cancer-free.His story is a reminder that survivorship is not merely about completing treatment. It is about
More news about: Apollo Hospitals
Jun 08, 2026, 00:41 ET Everything-PR Names the 100 People Shaping What AI Engines Say
publisherRonn Torossian is the founder and chairman of 5W AI Communications, the AI Communications Firm. He is the publisher of Everything-PR and the author of two best-selling editions of For Immediate Release.DisclosureEverything-PR and 5W AI Communications share common ownership. Everything-PR
More news about: 5W Public Relations
Jun 08, 2026, 00:30 ET PR Newswire Signs Affiliate Membership with PRCAI to Strengthen India's Communications Ecosystem
PRCAIFounded in 2001, the Public Relations Consultants Association of India (PRCAI) is the nation's most credible and influential communications body. For over two and a half decades, PRCAI has worked alongside its members to advance best practices, strengthen the profession, and nurture a world-class PR and communications
More news about: PR Newswire
Jun 08, 2026, 00:01 ET New IBM Study Finds CIOs and CTOs Face Growing AI Control Gap as Enterprise Deployment Scales
IBM) Institute for Business Value study reveals that as AI moves from experimentation to enterprise-wide deployment, two-thirds of surveyed CIOs and CTOs report being held accountable for AI systems they do not fully control, while governance struggles to keep pace at scale.
More news about: IBM
Jun 08, 2026, 00:01 ET Winning firms will focus on what they can control, weather the rest, as triple-shock brakes private equity's latest revival --Bain & Company 2026 Midyear PE report
2026, but cautions that a truly sustained PE upturn will depend on the market finding a more fundamental equilibrium lasting more than a quarter or two."There's no question the fog will lift eventually – it always does. The firms best positioning themselves to lead out of the present slump are
More news about: Bain & Company
Jun 08, 2026, 00:01 ET A Banner Year for Banks--and the Moment to Shift Gears on Growth, AI, and Innovation
up, with AI at the center. The gains are already measurable, and the gap between leaders and laggards is widening faster than was anticipated one or two years ago."Bold Growth Requires a Clear View of DisruptionFor institutions trading above book value, investing and targeting scalable
More news about: Boston Consulting Group (BCG)
Jun 07, 2026, 23:16 ET Sensing Meets Connectivity: Calterah Launches Ultra-Powerful mmWave Radar Chips for High-Performance ADAS and Leading-Edge UWB Radar Solutions
of IEEE 802.15.4ab Sensing in the Dubhe CAL1106AQ SoC and has released two groundbreaking solutions—a Child Presence Detection (CPD) development suite and a Parking Assist System (PAS) development suite. The two suites are both built on CAL1106AQ—the world's first IEEE 802.15.4ab-compliant
More news about: Calterah
Jun 07, 2026, 21:28 ET Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)
development.About CG2001CG2001 is a topical combination of minoxidil and finasteride developed to harness the synergistic potential of two cornerstone therapies for AGA. Both are widely recognized as first-line treatments for male pattern hair loss: minoxidil promotes hair growth, while
More news about: Dayspring Pharma
Jun 07, 2026, 20:10 ET Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
agonist. Global Phase III trials for obesity are expected to be initiated by the end of the third quarter of 2026. The Phase III program will comprise two 72-week randomized, double-blind, placebo-controlled studies in participants with obesity or overweight, with or without type 2 diabetes, evaluating
More news about: Ascletis Pharma Inc.
Jun 07, 2026, 20:08 ET OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
as a prospective, randomised, open-label, multi-centre registration trial evaluating the efficacy and safety of Ori-C101 in patients who have failed two or more prior lines of therapy. This marks the first GPC3-directed immune cell therapy anywhere in the world to enter a confirmatory trial, and
More news about: Oricell Therapeutics Holdings Limited
Jun 07, 2026, 18:52 ET Sportradar Group AG (SRAD) Investors: July 17, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP
compliance, investors learned the truth about the Company's intentional non-compliance with applicable laws and regulations on April 22, 2026, when two market research firms—Muddy Waters Research ("Muddy Waters") and Callisto Research ("Callisto")—separately published investigative reports revealing
More news about: Kessler Topaz Meltzer & Check, LLP
Jun 07, 2026, 17:30 ET Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
amylin analogs alongside GLP-1 RAs. In the REIMAGINE clinical trial program, researchers evaluated CagriSema, a medication that combines two medications—cagrilintide, which mimics amylin and semaglutide, a GLP-1 RA. The REIMAGINE studies are all randomized phase 3 clinical trials
More news about: American Diabetes Association
Jun 07, 2026, 16:45 ET AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
events as both high-risk primary and secondary prevention, with patients achieving and maintain dramatic LDL-C reductions using Repatha only once every two weeks.5,6Repatha was first approved in 2015 and has since been used by more than 8 million patients globally.7,8 In August
More news about: Amgen
Jun 07, 2026, 16:45 ET Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
caused by "bad" cholesterol (LDL-C).Phase 3 Data Highlights Potential of Olezarsen in Reducing TriglyceridesResearchers conducted two phase 3 randomized controlled trials, CORE-TIMI 72a (617 patients) and CORE2-TIMI 72b (446 patients), to evaluate the effectiveness of olezarsen, a targeted
More news about: American Diabetes Association
Jun 07, 2026, 10:30 ET MimiSilk Marks 12 Years of Advanced Care with New Product Launches and Anniversary Sale
technology into everyday life—safely, gently, and effectively. To mark this milestone, MimiSilk is celebrating its 12th anniversary with the launch of two new products and a month-long global promotion. The anniversary marks the brand's continued investment in making advanced
More news about: MimiSilk
Jun 07, 2026, 10:30 ET MimiSilk Marks 12 Years of Advanced Care with New Product Launches and Anniversary Sale
technology into everyday life—safely, gently, and effectively. To mark this milestone, MimiSilk is celebrating its 12th anniversary with the launch of two new products and a month-long global promotion. The anniversary marks the brand's continued investment in making advanced skincare more accessible to
More news about: MimiSilk